c‑Met affects gemcitabine resistance during carcinogenesis in a mouse model of pancreatic cancer

Noguchi,Kozo; Konno,Masamitsu; Eguchi,Hidetoshi; Kawamoto,Koichi; Mukai,Ryouta; Nishida,Naohiro; Koseki,Jun; Wada,Hiroshi; Akita,Hirofumi; Satoh,Taroh; Marubashi,Shigeru; Nagano,Hiroaki; Doki,Yuichiro; Mori,Masaki; Ishii,Hideshi

doi:10.3892/ol.2018.8793

c‑Met affects gemcitabine resistance during carcinogenesis in a mouse model of pancreatic cancer

Authors:
- Kozo Noguchi
- Masamitsu Konno
- Hidetoshi Eguchi
- Koichi Kawamoto
- Ryouta Mukai
- Naohiro Nishida
- Jun Koseki
- Hiroshi Wada
- Hirofumi Akita
- Taroh Satoh
- Shigeru Marubashi
- Hiroaki Nagano
- Yuichiro Doki
- Masaki Mori
- Hideshi Ishii
View Affiliations

Affiliations: Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka 565‑0871, Japan, Department of Frontier Science for Cancer and Chemotherapy, Graduate School of Medicine, Osaka University, Suita, Osaka 565‑0871, Japan, Department of Medical Data Science, Graduate School of Medicine, Osaka University, Suita, Osaka 565‑0871, Japan
Published online on: May 24, 2018 https://doi.org/10.3892/ol.2018.8793
Pages: 1892-1898

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pancreatic adenocarcinoma is thought to develop from histologically identifiable intraductal lesions known as pancreatic intraepithelial neoplasias (PanINs), which exhibit similar morphological and genetic features to pancreatic ductal adenocarcinoma (PDAC). Therefore, a better understanding of the biological features underlying the progression of PanIN is essential to development more effective therapeutic interventions for PDAC. In recent years, numerous studies have reported that MET proto‑oncogene receptor tyrosine kinase (c‑MET) is a potential marker of pancreatic cancer stem cells (CSCs). CSCs have been revealed to initiate and propagate tumors in vitro and in vivo, and are associated with a chemoresistant phenotype. However, in vivo models using a xenograft approach are limited. In the present study, the morphological phenotype, molecular alteration and biological behavior of neoplasia in Pdx‑1Cre/+, KrasLSL‑G12D/+ and Metflox/flox and wild‑type mice was analyzed. The results demonstrated that while oncogenic KrasLSL‑G12D/+ increased PanIN initiation and significantly decreased survival rate compared with wild‑type mice, no additive effect of c‑Met receptor signaling on PanIN progression or prognosis was observed. Following gemcitabine administration, c‑Met inhibition in Kras LSL‑G12D/+ mice significantly decreased the total surface area of PanIN lesions and the number of anti‑proliferation marker protein Ki‑67 positive cells occupying PanIN lesions compared with Met+/+ mice. In conclusion, complete inhibition of the c‑Met signaling pathway with chemotherapy may be useful for the treatment of pancreatic cancer.

View Figures

View References

1	Howe HL, Wu X, Ries LA, Cokkinides V, Ahmed F, Jemal A, Miller B, Williams M, Ward E, Wingo PA, et al: Annual report to the nation on the status of cancer, 1975–2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer. 107:1711–1742. 2006.
2	Majumder K, Gupta A, Arora N, Singh PP and Singh S: Premorbid obesity and mortality in patients with pancreatic cancer: A systematic review and meta-analysis. Clin Gastroenterol Hepatol. 14:355–368.e. 2016. View Article : Google Scholar : PubMed/NCBI
3	Pandol S, Gukovskaya A, Edderkaoui M, Dawson D, Eibl G and Lugea A: Epidemiology, risk factors, and the promotion of pancreatic cancer: Role of the stellate cell. J Gastroenterol Hepatol. 27(Suppl 2): S127–S134. 2012. View Article : Google Scholar
4	Rizwani W, Allen AE and Trevino JG: Hepatocyte growth factor from a clinical perspective: A pancreatic cancer challenge. Cancers (Basel). 7:1785–1805. 2015. View Article : Google Scholar : PubMed/NCBI
5	Ide T, Kitajima Y, Miyoshi A, Ohtsuka T, Mitsuno M, Ohtaka K and Miyazaki K: The hypoxic environment in tumor-stromal cells accelerates pancreatic cancer progression via the activation of paracrine hepatocyte growth factor/c-Met signaling. Ann Surg Oncol. 14:2600–2607. 2007. View Article : Google Scholar : PubMed/NCBI
6	Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature. 414:105–111. 2001. View Article : Google Scholar : PubMed/NCBI
7	Lonardo E, Hermann PC, Mueller MT, Huber S, Balic A, Miranda-Lorenzo I, Zagorac S, Alcala S, Rodriguez-Arabaolaza I, Ramirez JC, et al: Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell. 9:433–446. 2011. View Article : Google Scholar : PubMed/NCBI
8	Asukai K, Kawamoto K, Eguchi H, Konno M, Nishida N, Koseki J, Noguchi K, Hasegawa S, Ogawa H, Yamada D, et al: Prognostic impact of peritumoral IL-17-positive cells and IL-17 axis in patients with intrahepatic cholangiocarcinoma. Ann Surg Oncol. 22(Suppl 3): S1524–S1531. 2015. View Article : Google Scholar : PubMed/NCBI
9	Bai H, Li H, Zhang W, Matkowskyj KA, Liao J, Srivastava SK and Yang GY: Inhibition of chronic pancreatitis and pancreatic intraepithelial neoplasia (PanIN) by capsaicin in LSL-KrasG12D/Pdx1-Cre mice. Carcinogenesis. 32:1689–1696. 2011. View Article : Google Scholar : PubMed/NCBI
10	Shah AN, Zhang JM, Park SI, Parikh NU and Gallick GE: Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol. 14:3629–3637. 2007. View Article : Google Scholar : PubMed/NCBI
11	Koh YX, Chok AY, Zheng HL, Tan CS and Goh BK: A systematic review and meta-analysis of the clinicopathologic characteristics of cystic versus solid pancreatic neuroendocrine neoplasms. Surgery. 156:83–96.e2. 2014. View Article : Google Scholar : PubMed/NCBI
12	Wu WS: The signaling mechanism of ROS in tumor progression. Cancer Metastasis Rev. 25:695–705. 2006. View Article : Google Scholar : PubMed/NCBI
13	Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
14	Li C, Wu JJ, Hynes M, Dosch J, Sarkar B, Welling TH, Pasca di Magliano M and Simeone DM: c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology. 141:2218–2227.e5. 2011. View Article : Google Scholar : PubMed/NCBI
15	Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, Chen J, Wang X, Ruslim L, Blake R, et al: A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res. 63:7345–7355. 2003.PubMed/NCBI
16	Oshima Y, Suzuki A, Kawashimo K, Ishikawa M, Ohkohchi N and Taniguchi H: Isolation of mouse pancreatic ductal progenitor cells expressing CD133 and c-Met by flow cytometric cell sorting. Gastroenterology. 132:720–732. 2007. View Article : Google Scholar : PubMed/NCBI
17	Ohuchida K, Mizumoto K, Murakami M, Qian LW, Sato N, Nagai E, Matsumoto K, Nakamura T and Tanaka M: Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Res. 64:3215–3222. 2004. View Article : Google Scholar : PubMed/NCBI
18	Noguchi K, Eguchi H, Konno M, Kawamoto K, Nishida N, Koseki J, Wada H, Marubashi S, Nagano H, Doki Y, et al: Susceptibility of pancreatic cancer stem cells to reprogramming. Cancer Sci. 106:1182–1187. 2015. View Article : Google Scholar : PubMed/NCBI
19	Awad AJ, Burns TC, Zhang Y and Abounader R: Targeting MET for glioma therapy. Neurosurg Focus. 37:E102014. View Article : Google Scholar : PubMed/NCBI
20	Herreros-Villanueva M, Zubia-Olascoaga A and Bujanda L: c-Met in pancreatic cancer stem cells: Therapeutic implications. World J Gastroenterol. 18:5321–5323. 2012. View Article : Google Scholar : PubMed/NCBI
21	Peng Z, Zhu Y, Wang Q, Gao J, Li Y, Li Y, Ge S and Shen L: Prognostic significance of MET amplification and expression in gastric cancer: A systematic review with meta-analysis. PLoS One. 9:e845022014. View Article : Google Scholar : PubMed/NCBI
22	Inman KS, Francis AA and Murray NR: Complex role for the immune system in initiation and progression of pancreatic cancer. World J Gastroenterol. 20:11160–11181. 2014. View Article : Google Scholar : PubMed/NCBI
23	Pedica F, Beccari S, Pedron S, Montagna L, Piccoli P, Doglioni C and Chilosi M: PDX-1 (pancreatic/duodenal homeobox-1 protein 1). Pathologica. 106:315–321. 2014.PubMed/NCBI
24	Yu J, Ohuchida K, Mizumoto K, Ishikawa N, Ogura Y, Yamada D, Egami T, Fujita H, Ohashi S, Nagai E and Tanaka M: Overexpression of c-met in the early stage of pancreatic carcinogenesis; altered expression is not sufficient for progression from chronic pancreatitis to pancreatic cancer. World J Gastroenterol. 12:3878–3882. 2006. View Article : Google Scholar : PubMed/NCBI